Thermo Fisher Receives Buy Rating from Wells Fargo Analyst Brandon Couillard.

Thermo Fisher received a Buy rating from Wells Fargo with a $570 price target. Brandon Couillard from Wells Fargo maintains a Buy rating on the company, citing its strong position in the Healthcare sector. Thermo Fisher also received a Buy from Evercore ISI's Vijay Kumar, but was downgraded to a Hold by Scotiabank. The company has a one-year high of $627.88 and a one-year low of $385.46.

Thermo Fisher Scientific (TMO) has seen mixed analyst ratings and price targets recently, reflecting the complex dynamics of the healthcare sector. On July 2, 2025, Wells Fargo & Company upgraded TMO to a Buy rating with a price target of $570. Brandon Couillard, the analyst at Wells Fargo, highlighted the company's strong position in the Healthcare sector as a key factor in the upgrade [1].

Meanwhile, Evercore ISI's Vijay Kumar also maintained a Buy rating on TMO, further bolstering investor confidence in the company's prospects [1]. However, Scotiabank downgraded TMO to a Hold rating, indicating a more cautious outlook on the stock's performance [1].

The company's stock has seen significant volatility over the past year, with a one-year high of $627.88 and a one-year low of $385.46. Despite the mixed ratings, the overall consensus rating remains "Moderate Buy," suggesting that the majority of analysts are optimistic about TMO's long-term potential [1].

Investors should closely monitor the company's earnings reports and any significant developments in the Healthcare sector to make informed decisions about TMO's stock. The mixed analyst ratings and price targets highlight the importance of thorough research and diversification in investment strategies.

References:
[1] https://www.marketbeat.com/stocks/NYSE/TMO/forecast/